Share on StockTwits

United Therapeutics (NASDAQ:UTHR) COO Roger Jeffs unloaded 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $96.29, for a total transaction of $962,900.00. Following the completion of the sale, the chief operating officer now directly owns 1,234 shares of the company’s stock, valued at approximately $118,822. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 2.10% on Wednesday, hitting $98.37. 518,476 shares of the company’s stock traded hands. United Therapeutics has a 1-year low of $61.23 and a 1-year high of $116.65. The stock has a 50-day moving average of $99.16 and a 200-day moving average of $99.55. The company has a market cap of $4.739 billion and a price-to-earnings ratio of 20.93.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, April 29th. The company reported $1.77 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $7.77 earnings per share for the current fiscal year.

UTHR has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Finally, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company. United Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $95.93.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.